France has taken a landmark step in its commitment to early access pathways for diagnostic innovation. On 5 June 2025, the Haute Autorité de Santé (HAS) published its first formal decision under …
Odelle Technology
-
News
-
As of April 2025, France’s Reimbursed Early Access Program (AAP, formerly ATU) continues to stand as one of Europe’s most advanced pathways for granting early, publicly funded access to life-saving therapies, even …
-
This weekend’s Independent ran a provocative headline:“Obese patients denied joint replacements in bid to slash NHS costs.” The story revealed that one-third of NHS Integrated Care Boards (ICBs) in England, and some in …
-
Over the past decade, the European Economic Area (EEA) has seen a marked decline in its role as a hub for clinical trials. In 2013, approximately 22% of global industry-sponsored …
-
News
How NICE Evaluates AI in Skin Cancer Pathways: A Deep Dive into HTE24 and the Role of Evidence Generation
The National Institute for Health and Care Excellence (NICE) recently published its HTE24 guidance under the Health Technology Evaluation (HTE) programme, marking a milestone for artificial intelligence in dermatology. At the centre of this …
-
News
Harmonising Diagnostics in Finland: The Story Behind the Laboratory Tests Nomenclature and Its 2025 Update
In an era defined by digital health transformation and data-driven care, Finland continues to lead in diagnostic interoperability, public reimbursement integration and laboratory standardisation. At the heart of this ecosystem …
-
Rethinking Reimbursement: France’s Article 51 as a Model for Real-World Innovation In 2018, France introduced a powerful tool to reshape its health system from within: Article 51 of the Loi de Financement de …
-
In the two decades since the arrival of robotic-assisted surgery (RAS), clinical teams across urology, colorectal, gynaecological and orthopaedic domains have embraced its ergonomic advantages, precision tooling and potential for …
-
Melanoma has seen an extraordinary therapeutic revolution over the past decade, with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, ipilimumab) and BRAF/MEK inhibitors (e.g. dabrafenib/trametinib, vemurafenib/cobimetinib) substantially improving survival. However, the …
-
The National Institute for Health and Care Excellence (NICE) has recently updated its Real-World Evidence (RWE) Framework, formally recognising qualitative research as an important contributor to health technology assessment (HTA) in England. This …